Biblio

Author Title Type [ Year(Asc)]
Filters: First Letter Of Last Name is V  [Clear All Filters]
2018
Eekers DBP, Ven Lin 't, Deprez S, et al. The posterior cerebellum, a new organ at risk?. Clinical and Translational Radiation Oncology. 2018;8:22 - 26. doi:10.1016/j.ctro.2017.11.010.
2017
Larue RTHM, Van De Voorde L, van Timmeren JE, et al. Data from: 4DCT imaging to assess radiomics feature stability: an investigation for thoracic cancers. 2017. doi:10.17195/candat.2017.05.1.
Larue RTHM, Van De Voorde L, van Timmeren JE, et al. Data from: 4DCT imaging to assess radiomics feature stability: an investigation for thoracic cancers. 2017. doi:10.17195/candat.2017.05.1.
Larue RTHM, Van De Voorde L, van Timmeren JE, et al. Data from: 4DCT imaging to assess radiomics feature stability: an investigation for thoracic cancers. 2017. doi:10.17195/candat.2017.05.1.
Jochems A, Deist TM, Naqa IEl, et al. Data from: Developing and validating a survival prediction model for NSCLC patients through distributed learning across three countries. 2017. doi:10.17195/candat.2017.02.2.File Jochems-2017-MaastroDataUnbinned.csv (62.76 KB)
van Timmeren J, Leijenaar RTH, van Elmpt W, et al. Data from: Survival prediction of non-small cell lung cancer patients using radiomics analyses of cone-beam CT images. 2017. doi:10.17195/candat.2017.02.1.Package icon Van-Timmeren_2017_cases-001-020.zip (750.99 MB)Package icon Van-Timmeren_2017_cases-021-040.zip (726.98 MB)Package icon Van-Timmeren_2017_cases-041-060.zip (777.6 MB)Package icon Van-Timmeren_2017_cases-061-080.zip (795.72 MB)Package icon Van-Timmeren_2017_cases-081-102.zip (827.01 MB)
van Timmeren J, Leijenaar RTH, van Elmpt W, et al. Data from: Survival prediction of non-small cell lung cancer patients using radiomics analyses of cone-beam CT images. 2017. doi:10.17195/candat.2017.02.1.Package icon Van-Timmeren_2017_cases-001-020.zip (750.99 MB)Package icon Van-Timmeren_2017_cases-021-040.zip (726.98 MB)Package icon Van-Timmeren_2017_cases-041-060.zip (777.6 MB)Package icon Van-Timmeren_2017_cases-061-080.zip (795.72 MB)Package icon Van-Timmeren_2017_cases-081-102.zip (827.01 MB)
2016
Reymen B, van Gisbergen MW, Even AJG, et al. Data from: Nitroglycerin in non-small cell lung cancer: does it impact tumor hypoxia and tumor perfusion? A window-of-opportunity clinical trial. 2016. doi:10.17195/candat.2016.07.2.Package icon 2017-08-28 Reymen - Nitro database HX-4 DCECT clean.zip (20.3 KB)
Reymen B, van Gisbergen MW, Even AJG, et al. Data from: Nitroglycerin in non-small cell lung cancer: does it impact tumor hypoxia and tumor perfusion? A window-of-opportunity clinical trial. 2016. doi:10.17195/candat.2016.07.2.Package icon 2017-08-28 Reymen - Nitro database HX-4 DCECT clean.zip (20.3 KB)
Even A, Hamming-Vrieze O, van Elmpt W, et al. Data from: Quantitative assessment of Zirconium-89 labeled cetuximab using PETCT imaging in patients with advanced head and neck cancer - a theragnostic approach. 2016. doi:10.17195/candat.2016.11.1.Package icon Even_P0037C0006I4475579.ZIP (97.26 MB)Package icon Even_P0037C0006I5879176.ZIP (131.21 MB)Package icon Even_P0037C0006I6042760.ZIP (115.71 MB)Package icon Even_P0037C0006I8991415.ZIP (101.03 MB)
Even A, Hamming-Vrieze O, van Elmpt W, et al. Data from: Quantitative assessment of Zirconium-89 labeled cetuximab using PETCT imaging in patients with advanced head and neck cancer - a theragnostic approach. 2016. doi:10.17195/candat.2016.11.1.Package icon Even_P0037C0006I4475579.ZIP (97.26 MB)Package icon Even_P0037C0006I5879176.ZIP (131.21 MB)Package icon Even_P0037C0006I6042760.ZIP (115.71 MB)Package icon Even_P0037C0006I8991415.ZIP (101.03 MB)
Even A, Hamming-Vrieze O, van Elmpt W, et al. Data from: Quantitative assessment of Zirconium-89 labeled cetuximab using PETCT imaging in patients with advanced head and neck cancer - a theragnostic approach. 2016. doi:10.17195/candat.2016.11.1.Package icon Even_P0037C0006I4475579.ZIP (97.26 MB)Package icon Even_P0037C0006I5879176.ZIP (131.21 MB)Package icon Even_P0037C0006I6042760.ZIP (115.71 MB)Package icon Even_P0037C0006I8991415.ZIP (101.03 MB)
Even A, Hamming-Vrieze O, van Elmpt W, et al. Data from: Quantitative assessment of Zirconium-89 labeled cetuximab using PETCT imaging in patients with advanced head and neck cancer - a theragnostic approach. 2016. doi:10.17195/candat.2016.11.1.Package icon Even_P0037C0006I4475579.ZIP (97.26 MB)Package icon Even_P0037C0006I5879176.ZIP (131.21 MB)Package icon Even_P0037C0006I6042760.ZIP (115.71 MB)Package icon Even_P0037C0006I8991415.ZIP (101.03 MB)
2015
Walsh S, Roelofs E, Kuess P, et al. Data from: A validated Tumor Control Probability model based on a meta-analysis of low, intermediate, and high-risk prostate cancer patients treated by photon, proton, or carbon-ion radiotherapy. 2015. doi:10.17195/candat.2015.10.8.File Walsh - TCP meta-analysis of patients treated with photon, proton and c-ion radiotherapy (CSV) (15.82 KB)File Walsh - TCP meta-analysis of patients treated with photon, proton and c-ion radiotherapy (XLS) (13.85 KB)
Cheng Q, Roelofs E, Ramaekers B, et al. Data from: Development and Evaluation of an Online Three-Level Proton vs Photon Decision Support Prototype for Head and Neck Cancer - Comparison of Dose, Toxicity and Cost-Effectiveness. 2015. doi:10.17195/candat.2015.10.5.File PRODECIS-HNC-results.xlsx (43.25 KB)Image icon PRODECIS-HNC-Figure-2.png (47.07 KB)
Cheng Q, Roelofs E, Ramaekers B, et al. Data from: Development and Evaluation of an Online Three-Level Proton vs Photon Decision Support Prototype for Head and Neck Cancer - Comparison of Dose, Toxicity and Cost-Effectiveness. 2015. doi:10.17195/candat.2015.10.5.File PRODECIS-HNC-results.xlsx (43.25 KB)Image icon PRODECIS-HNC-Figure-2.png (47.07 KB)
Panth K, van den Beucken T, Biemans R, et al. Data from: MMP2 small immuno protein antibody uptake in xenograft tumors is associated with MMP2 activity. 2015. doi:10.17195/candat.2015.10.6.File Panth_MMP2-activity-vs-uptake.csv (2.03 KB)File Panth_MMP2-analysis.csv (6.1 KB)File Panth_MMP2-representative-images.rar (570.44 KB)
Even AJG, van der Stoep J, Zegers CML, et al. PET-based dose painting in non-small cell lung cancer: Comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes. Radiother Oncol. 2015;116(2):281-6. doi:10.1016/j.radonc.2015.07.013.
Even AJG, van der Stoep J, Zegers CML, et al. PET-based dose painting in non-small cell lung cancer: Comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes. Radiother Oncol. 2015;116(2):281-6. doi:10.1016/j.radonc.2015.07.013.
Oberije C, De Ruysscher D, Houben R, et al. A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients. Int J Radiat Oncol Biol Phys. 2015;92(4):935-44. doi:10.1016/j.ijrobp.2015.02.048.
Error | CancerData.org

Error

The website encountered an unexpected error. Please try again later.